Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQCXSG)

• Drug Name: Avexitide Drug Info
• Synonyms: Avexitide; Avexitide [USAN]; Exendin (9-39); Exendin 9-39; Exendin(9-39)amide; Exendin-(9-39); 5313W10MYT; UNII-5313W10MYT; Exendin 3 (heloderma horridum), 1-de-L-histidine-2-de-L-serine-3-de-L-aspartic acid-4-deglycine-5-de-L-threonine-6-de-L-phenylalanine-7-de-L-threonine-8-de-L-serine-; Exendin-3 (9-39) amide; exendin(9-39); AVEXITIDE [INN]; Exendin (9-39) amide; GTPL1138; EXENDIN (9-39) [MI]; DB14806; 9-39-EXENDIN 4 (HELODERMA SUSPECTUM); ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-LLE-GLU-TRP-LEU-LYS-ASN-GIY-GIY-PRO-SER-SER-GIY-ALA-PRO-PRO-PRO-SER-NH2; L-SERINAMIDE, L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-METHIONYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-VALYL-L-ARGINYL-L-LEUCYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-ASPARAGINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-

Indication

Disease Entry	ICD 11	Status	REF
Congenital hyperinsulinism	5A4Y	Phase 2	[1]
Hypoglycemia	5A41	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 129012199
  TTD Drug ID: DMQCXSG

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semaglutide	DMAGFOD	Type-2 diabetes	5A11	Approved	[4]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[5]
Exenatide	DMYHBKN	Inflammation	1A00-CA43.1	Approved	[6]
Dulaglutide	DMYXBV3	Type-2 diabetes	5A11	Approved	[7]
Lixisenatide	DM0QJDC	Type-2 diabetes	5A11	Approved	[8]
Pramlintide	DM0EZ9Q	Type-1/2 diabetes	5A10-5A11	Approved	[5]
Albiglutide	DM1JEGF	Type-2 diabetes	5A11	Approved	[8]
Tirzepatide	DMQNMAT	Type 2 diabetes	5A11	Approved	[9]
Efpeglenatide	DMKA2PI	Type-2 diabetes	5A11	Phase 3	[10]
GLP-1	DMR6YH3	Diabetic complication	5A2Y	Phase 3	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT04652479) A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03373435) A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia. U.S.National Institutes of Health.
• [3] PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3235-e3248.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
• [5] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [6] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [7] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [8] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
• [9] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)